Topoisomerase II a (TOP2A) can be a useful gene in determining whether TNBC patients would have a good response to anthracycline therapy, which is the mainstay treatment in TNBC cancer (Brase et al., 2010; Di Leo et al., 2011; Eltohamy et al., 2018). This evidence concerns the gene TOP2A and cancer.